Drug Trial Radar · NCT00143611
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis
Last checked: Nov 20, 2026Latest source record: Feb 2, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
277
Actual
Start
Sep 2005
Primary completion
Feb 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the optimal dose of Resatorvid for reducing 28-day all-cause mortality in subjects with severe sepsis.
Conditions
- Sepsis
Interventions
ResatorvidDrug
Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
ResatorvidDrug
Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
PlaceboDrug
Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 28-day All-cause Mortality.Time frame: Day 28
Locations
144 sites in 17 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Escondido, California
Site not named
Los Angeles, California
Site not named
Orange, California
Site not named
Poway, California
Site not named
San Diego, California
Site not named
Colorado Springs, Colorado
Site not named
New Haven, Connecticut
Site not named
Newark, Delaware
Site not named
Atlantis, Florida
Site not named
Bay Pines, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Sarasota, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Peoria, Illinois
Site not named
Indianapolis, Indiana
Site not named
Des Moines, Iowa
Site not named
Louisville, Kentucky
Site not named
Shreveport, Louisiana
Site not named
Portland, Maine
Site not named
Baltimore, Maryland
Site not named
Springfield, Massachusetts
Site not named
Kalamazoo, Michigan
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Butte, Montana
Site not named
Englewood, New Jersey
Site not named
Buffalo, New York
Site not named
New York, New York
Site not named
Rochester, New York
Site not named
Greensboro, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Akron, Ohio
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.